Cristina E Tognon Selected Research

Secretory breast carcinoma

12/2007	ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex.
2/2004	A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cristina E Tognon Research Topics

Disease

19	Neoplasms (Cancer) 03/2021 - 08/2002
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2021 - 06/2015
7	Leukemia 12/2021 - 05/2013
3	Carcinogenesis 01/2018 - 02/2004
3	Breast Neoplasms (Breast Cancer) 12/2012 - 12/2007
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 01/2017
2	Polycythemia Vera 01/2020 - 01/2018
2	BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative) 01/2020 - 12/2015
2	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 01/2017
2	Secretory breast carcinoma 12/2007 - 02/2004
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021
1	Chronic Neutrophilic Leukemia 01/2020
1	Philadelphia Chromosome 10/2019
1	Splenomegaly 01/2018
1	Acquired Immunodeficiency Syndrome (AIDS) 10/2017
1	Melanoma (Melanoma, Malignant) 12/2015
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 06/2015
1	Sarcoma (Soft Tissue Sarcoma) 02/2004

Drug/Important Bio-Agent (IBA)

9	Phosphotransferases (Kinase)IBA 01/2020 - 02/2004
5	Pharmaceutical PreparationsIBA 03/2021 - 01/2017
4	Oncogene Proteins (Oncogene Protein)IBA 10/2018 - 06/2004
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2018 - 02/2004
4	Insulin-Like PeptidesIBA 12/2012 - 08/2002
3	venetoclaxIBA 07/2021 - 01/2019
3	Tyrosine Kinase InhibitorsIBA 01/2021 - 10/2019
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 01/2018
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2020 - 10/2018
2	ruxolitinibIBA 01/2020 - 02/2016
2	ponatinibIBA 01/2020 - 10/2019
2	Tyrosine (L-Tyrosine)FDA Link 10/2018 - 01/2018
2	Transcription Factors (Transcription Factor)IBA 01/2018 - 02/2004
2	Phenobarbital (Luminal)FDA Link 02/2011 - 12/2007
1	gilteritinibIBA 12/2021
1	Biological ProductsIBA 03/2021
1	larotrectinibIBA 11/2020
1	entrectinibIBA 11/2020
1	midostaurinIBA 07/2020
1	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 01/2020
1	Erythropoietin FDA Link 01/2020
1	ibrutinibIBA 01/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 10/2018
1	Metformin (Glucophage)FDA LinkGeneric 01/2018
1	BiguanidesIBA 01/2018
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	CytokinesIBA 10/2017
1	Drug CombinationsIBA 01/2017
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2015
1	trametinibIBA 12/2015
1	Anaplastic Lymphoma KinaseIBA 06/2015
1	Proteins (Proteins, Gene)FDA Link 05/2015
1	Insulin-Like Growth Factor Binding ProteinsIBA 12/2012
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2012
1	BMS 754807IBA 02/2011
1	IGF Type 1 Receptor (IGF 1 Receptor)IBA 02/2011
1	matrigelIBA 02/2011
1	Insulin ReceptorIBA 02/2011
1	BMS 536924IBA 02/2011
1	tyrosine receptor (receptor, tyrosine)IBA 02/2004
1	Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA 02/2004

Therapy/Procedure

10	Therapeutics 07/2021 - 01/2012
1	Precision Medicine 10/2017
1	Caloric Restriction 05/2013